Catalyst

Slingshot members are tracking this event:

REGENXBIO and Biogen Enter Exclusive License Agreement for the Development of Gene Therapy Treatments for Rare Genetic Vision Disorders

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
RGNX Community voting in process
BIIB Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 16, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords License Agreement, Rare Genetic Vision Disorders, Gene Therapy Treatments